Denis B Buxton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8654269/publications.pdf Version: 2024-02-01

		566801	476904
30	1,114	15	29
papers	citations	h-index	g-index
31 all docs	31 docs citations	31 times ranked	1552 citing authors

DENIS R RUYTON

#	Article	IF	CITATIONS
1	A Summary of the American Society of Echocardiography Foundation Value-Based Healthcare: Summit 2014. Journal of the American Society of Echocardiography, 2015, 28, 755-769.	1.2	15
2	American Society of Echocardiography Cardiovascular Technology and Research Summit: A Roadmap for 2020. Journal of the American Society of Echocardiography, 2013, 26, 325-338.	1.2	34
3	Support for Cardiovascular Cell Therapy Research at the National Heart, Lung, and Blood Institute. Circulation Research, 2012, 110, 1549-1555.	2.0	4
4	Molecular Imaging of Aortic Aneurysms. Circulation: Cardiovascular Imaging, 2012, 5, 392-399.	1.3	10
5	The impact of nanotechnology on myocardial infarction treatment. Nanomedicine, 2012, 7, 173-175.	1.7	10
6	Nanotechnology Research Support at the National Heart, Lung, and Blood Institute. Circulation Research, 2011, 109, 250-254.	2.0	5
7	Report of the National Heart, Lung, and Blood Institute Working Group on the Translation of Cardiovascular Molecular Imaging. Circulation, 2011, 123, 2157-2163.	1.6	47
8	Nanomedicine in Blood Diseases. , 2011, , .		0
9	Current status of nanotechnology approaches for cardiovascular disease: a personal perspective. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 149-155.	3.3	29
10	Nanomedicine for the management of lung and blood diseases. Nanomedicine, 2009, 4, 331-339.	1.7	67
11	Nanotechnology in the diagnosis and management of heart, lung and blood diseases. Expert Review of Molecular Diagnostics, 2007, 7, 149-160.	1.5	20
12	The promise of nanotechnology for heart, lung and blood diseases. Expert Opinion on Drug Delivery, 2006, 3, 173-175.	2.4	8
13	Nonmuscle Myosin IIB Is Involved in the Guidance of Fibroblast Migration. Molecular Biology of the Cell, 2004, 15, 982-989.	0.9	211
14	Cytokines and Late Preconditioning. Cardiovascular Research, 2004, 64, 6-8.	1.8	3
15	A single class II myosin modulates T cell motility and stopping, but not synapse formation. Nature Immunology, 2004, 5, 531-538.	7.0	177
16	Induction of Nonmuscle Myosin Heavy Chain II-C by Butyrate in RAW 264.7 Mouse Macrophages. Journal of Biological Chemistry, 2003, 278, 15449-15455.	1.6	23
17	Glucose metabolism in reperfused myocardium measured by [2-18F] 2-fluorodeoxyglucose and PET. Cardiovascular Research, 2000, 45, 321-329.	1.8	15
18	Calcium-dependent Threonine Phosphorylation of Nonmuscle Myosin in Stimulated RBL-2H3 Mast Cells. Journal of Biological Chemistry, 2000, 275, 34772-34779.	1.6	18

DENIS B BUXTON

#	Article	IF	CITATIONS
19	Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1406, 62-72.	1.8	39
20	Stimulation of c-Jun Kinase and Mitogen-Activated Protein Kinase by Ischemia and Reperfusion in the Perfused Rat Heart. Biochemical and Biophysical Research Communications, 1996, 218, 83-88.	1.0	171
21	Inhibition of glyceraldehyde-3-phosphate dehydrogenase in post-ischaemic myocardium. Cardiovascular Research, 1996, 32, 1016-1023.	1.8	46
22	Effect of exercise supplementation during adenosine infusion on hyperemic blood flow and flow reserve. American Heart Journal, 1994, 128, 52-60.	1.2	26
23	Responses of blood flow, oxygen consumption, and contractile function to inotropic stimulation in stunned canine myocardium. American Heart Journal, 1994, 127, 1251-1262.	1.2	24
24	Metabolism in Non-ischemic Myocardium during Coronary Artery Occlusion and Reperfusion. Journal of Molecular and Cellular Cardiology, 1993, 25, 667-681.	0.9	8
25	Cardiac positron emission tomography. Journal of Thoracic Imaging, 1990, 5, 9-19.	0.8	1
26	Potentiation of the glycogenolytic and haemodynamic actions of adenosine in the perfused rat liver by verapamil. European Journal of Pharmacology, 1988, 146, 121-127.	1.7	4
27	AGEPC: A Potent Calcium-Dependent Chemical Mediator in the Liver. Advances in Experimental Medicine and Biology, 1988, 232, 203-212.	0.8	1
28	Activation of hepatic glycogenolysis by phagocytic stimulation. Bioscience Reports, 1987, 7, 485-490.	1.1	0
29	Specific antagonists of platelet activating factor-mediated vasoconstriction and glycogenolysis in the perfused rat liver. Biochemical Pharmacology, 1986, 35, 893-897.	2.0	14
30	The effects of cyclopropane carboxylic acid on hepatic pyruvate metabolism. Metabolism: Clinical and Experimental, 1983, 32, 736-744.	1.5	7